The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
The protocol involves using CRISPR-Cas9 gene editing to knock out the NRF2 gene in KRAS-positive NSCLC patients who have become resistant to chemotherapy.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
Mismatch repair-deficient tumors with many insertion-deletion mutations and enhanced microsatellite instability responded better to anti-PD-1 immunotherapy.
The researchers said their findings could help classify BRCA1 variants, particularly one whose impact on cancer risk is currently not clear.